Clinical Trials · NCT07310420
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
- Phase
- Phase 1
- Recruitment status
- Recruiting
- Sponsor
- TerSera Therapeutics LLC
- Enrollment
- 176
- Start date
- Oct 2026
- Locations
- 23 sites, United States
- Primary endpoint
- Percentage of Participants with LH Values Below a Specified Threshold at Week 6 Within Each Cohort